Your browser doesn't support javascript.
loading
MicroRNA Expression in KRAS- and BRAF-mutated Colorectal Cancers.
Lundberg, Ida V; Wikberg, Maria L; Ljuslinder, Ingrid; Li, Xingru; Myte, Robin; Zingmark, Carl; Löfgren-Burström, Anna; Edin, Sofia; Palmqvist, Richard.
Afiliação
  • Lundberg IV; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden ida.lundberg@umu.se.
  • Wikberg ML; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden.
  • Ljuslinder I; Department of Radiation Sciences, Oncology, Umeå University, Umea, Sweden.
  • Li X; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden.
  • Myte R; Department of Radiation Sciences, Oncology, Umeå University, Umea, Sweden.
  • Zingmark C; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden.
  • Löfgren-Burström A; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden.
  • Edin S; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden.
  • Palmqvist R; Department of Medical Biosciences, Pathology, Umeå University, Umea, Sweden.
Anticancer Res ; 38(2): 677-683, 2018 02.
Article em En | MEDLINE | ID: mdl-29374690
BACKGROUND/AIM: KRAS and BRAF are two genes commonly mutated in colorectal cancer (CRC). Even though BRAF is a downstream target of KRAS in the MAPK signalling pathway, KRAS- and BRAF-mutated CRCs are found to display several different clinical and histopathological features. We investigated whether a differential expression of microRNAs (miRNAs) could explain the clinicopathological differences seen between KRAS- and BRAF-mutated CRCs. MATERIALS AND METHODS: Using a PCR array, we analyzed the expression of 84 different miRNAs in CRC cell lines wild-type in KRAS and BRAF, or mutated in KRAS or BRAF. RESULTS: Ten miRNAs were selected for further analyses in tumor tissue specimens (let-7a, let-7i, miR-10a, miR-10b, miR-31, miR-100, miR-181a, miR-181b, miR-372, and miR-373). BRAF-mutated tumors were found to express significantly higher levels of miR-31 as well as significantly lower levels of miR-373, compared to wild-type tumors. CONCLUSION: Our results suggest that KRAS- and BRAF-mutated CRCs may have different miRNA signatures compared to CRC tumors wild-type in KRAS and BRAF. However, no difference in expression levels between KRAS- and BRAF-mutated tumors was evident for the miRNAs analyzed in this study.
Assuntos
Palavras-chave
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / MicroRNAs / Proteínas Proto-Oncogênicas B-raf Limite: Humans Idioma: En Revista: Anticancer Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suécia
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteínas Proto-Oncogênicas p21(ras) / MicroRNAs / Proteínas Proto-Oncogênicas B-raf Limite: Humans Idioma: En Revista: Anticancer Res Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suécia